OncoSignal
Live from Open Targets Platform, fetched 2026-11-11 21:51 UTC. Every row links to its source record.

PTEN phosphatase and tensin homolog

ENSG00000171862 · protein coding · Open Targets profile

Dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine-phosphorylated proteins (PubMed:9187108, PubMed:9256433, PubMed:9616126). Also functions as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring of PtdIns(3,4,5)P3/phosphatidylinositol 3,4,5- trisphosphate, PtdIns(3,4)P2/phosphatidylinositol 3,4-diphosphate and PtdIns3P/phosphatidylinositol 3-phosphate with a preference for PtdIns(3,4,5)P3 (PubMed:16824732, PubMed:26504226, PubMed:9593664, PubMed:9811831). Furthermore, this enzyme can also act as a cytosolic inositol 3-phosphatase acting on Ins(1,3,4,5,6)P5/inositol 1,3,4,5,6 pentakisphosphate and possibly Ins(1,3,4,5)P4/1D-myo-inositol 1,3,4,5- tetrakisphosphate (PubMed:11418101, PubMed:15979280). Antagonizes the PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides and thereby modulating cell cycle progression and cell survival (PubMed:31492966, PubMed:37279284). The unphosphorylated form cooperates with MAGI2 to suppress AKT1 activation (PubMed:11707428). In motile cells, suppresses the formation of lateral pseudopods and thereby promotes cell polarization and directed movement (PubMed:22279049). Dephosphorylates tyrosine-phosphorylated focal adhesion kinase and inhibits cell migration and integrin-mediated cell spreading and focal adhesion formation (PubMed:22279049). Required for growth factor-induced epithelial cell migration; growth factor stimulation induces PTEN phosphorylation which changes its binding preference from the p85 regulatory subunit of the PI3K kinase complex to DLC1 and results in translocation of the PTEN-DLC1 complex to the posterior of migrating cells to promote RHOA activation (PubMed:26166433). Meanwhile, TNS3 switches binding preference from DLC1 to p85 and the TNS3-p85 complex translocates to the leading edge of migrating cells to activate RAC1 activation (PubMed:26166433). Plays a role as a key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation (By similarity). Involved in the regulation of synaptic function in excitatory hippocampal synapses. Recruited to the postsynaptic membrane upon NMDA receptor activation, is required for the modulation of synaptic activity during plasticity. Enhancement of lipid phosphatase activity is able to drive depression of AMPA receptor-mediated synaptic responses, activity required for NMDA receptor-dependent long-term depression (LTD) (By similarity). May be a negative regulator of insulin signaling and glucose metabolism in adipose tissue. The nuclear monoubiquitinated form possesses greater apoptotic potential, whereas the cytoplasmic nonubiquitinated form induces less tumor suppressive ability (PubMed:10468583, PubMed:18716620). {ECO:0000250|UniProtKB:O08586, ECO:0000250|UniProtKB:O54857, ECO:0000269|PubMed:10468583, ECO:0000269|PubMed:11418101, ECO:0000269|PubMed:11707428, ECO:0000269|PubMed:15979280, ECO:0000269|PubMed:16824732, ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:22279049, ECO:0000269|PubMed:26166433, ECO:0000269|PubMed:26504226, ECO:0000269|PubMed:31492966, ECO:0000269|PubMed:37279284, ECO:0000269|PubMed:9187108, ECO:0000269|PubMed:9256433, ECO:0000269|PubMed:9593664, ECO:0000269|PubMed:9616126, ECO:0000269|PubMed:9811831}.

In 10 of 15 cancers, the evidence for PTEN comes mainly from inherited variants

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751PTEN hamartoma tumor syndromePTEN hamartoma tumor syndromePTEN hamartoma tumor syndrome: somatic 0.75PTEN hamartoma tumor syndrome: germline 0.97glioma susceptibility 2glioma susceptibility 2glioma susceptibility 2: germline 0.86Bannayan-Riley-Ruvalcaba syndromeBannayan-Riley-Ruvalcaba syndromeBannayan-Riley-Ruvalcaba syndrome: germline 0.68gliomagliomaglioma: somatic 0.46glioma: germline 0.72endometrial cancerendometrial cancerendometrial cancer: somatic 0.87melanomamelanomamelanoma: somatic 0.81head and neck squamous cell carcinomahead and neck squamous cell carcinomahead and neck squamous cell carcinoma: somatic 0.52head and neck squamous cell carcinoma: germline 0.53Familial prostate cancerFamilial prostate cancerFamilial prostate cancer: germline 0.90familial meningiomafamilial meningiomafamilial meningioma: germline 0.90prostate adenocarcinomaprostate adenocarcinomaprostate adenocarcinoma: somatic 0.85prostate carcinomaprostate carcinomaprostate carcinoma: somatic 0.64prostate carcinoma: germline 0.06Lhermitte-Duclos diseaseLhermitte-Duclos diseaseLhermitte-Duclos disease: germline 0.66prostate cancerprostate cancerprostate cancer: germline 0.88meningiomameningiomameningioma: somatic 0.46meningioma: germline 0.55endometrial carcinomaendometrial carcinomaendometrial carcinoma: somatic 0.72endometrial carcinoma: germline 0.71

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Small molecule
Structure with Ligand
Antibody
UniProt loc high conf, GO CC high conf
PROTAC
UniProt Ubiquitination, Database Ubiquitination, Half-life Data, Small Molecule Binder

gnomAD loss of function constraint: o/e 0.4070200026035309 (upper bound 0.5972300171852112). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of PTEN's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of PTEN's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.